<DOC>
	<DOCNO>NCT00558844</DOCNO>
	<brief_summary>This study determine safety tolerability 28 day daily dose 560 mg Arikace™ versus placebo patient Cystic fibrosis .</brief_summary>
	<brief_title>Multidose Safety Tolerability Study Liposomal Amikacin Inhalation ( Arikace™ ) In Cystic Fibrosis Patients</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) gentic disease result mutation 230 kb gene chromosome 7 know cystic fibrosis transmembrane conductance regulator ( CFTR ) . Study subject CF manifest pathological change variety organs express CFTR . The lung frequently affect , sequelae chronic infection airway inflammation . The principal goal treatment subject CF slow chronic deterioration lung function . Study subject randomize receive either study drug placebo ( 1.5 % NaCl ) inhalation via PARI eFlow nebulizer . Each subject complete 28 day daily dose . All study patient follow safety , pharmacokinetics , clinical microbiologic activity 56 day post completion study treatment . The total study period 84 day , screen visit occur within precede 14 day prior study day 1 . Patients clinically evaluate first 48 hour post first study dose weekly 28 day treatment period follow visit study day 35 , 42 , 49 , 56 , 70 85 day determine safety tolerability , pharmacokinetics ( PK ) clinical microbiologic activity . Clinical laboratory parameter , audiology testing , clinical adverse event pulmonary function evaluate study subject order determine qualitative quantitative safety tolerability Arikace™ compare placebo . Serum , urine sputum specimen collect periodic interval assess PK . Additionally , sputum sample collect determine change bacterial density . Pulmonary function test CFQ-R measurement assess select time point throughout study . An exploratory evaluation Cystic Fibrosis Symptom Diary ( CFSD ) also implement .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Male female study subject must adults ( ≥ 6 year age ) Confirmed diagnosis CF History chronic infection P.aeruginosa FEV1 ≥40 % predict Screening Ability comply study medication use , study visit procedure Ability produce 0.5 gram sputum Administration investigational drug within 8 week Study Day 1 Emergency room visit hospitalization CF respiratoryrelated illness within 4 week prior screen History alcohol , medication illicit drug abuse within 1 yr. screen History lung transplantation Female childbearing potential practicing acceptable method birth control lactate Positive Pregnancy test Use antipseudomonal antibiotic within 28 day prior Study Day 1 Initiation chronic therapy within 28 day prior Study Day 1 History sputum throat swab culture yield Burkholderia cepacia within 2 year prior screen History mycobacterial and/or Aspergillus infection require treatment within 2 year prior screen History biliary cirrhosis portal hypertension , splenomegaly</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Respiratory Infections</keyword>
	<keyword>Pulmonary Cystic Fibrosis</keyword>
	<keyword>CFTR</keyword>
</DOC>